|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
Pre-market 14:39:36 | |||
| 57.29 USD | +28.25% |
|
56.05 | -2.16% |
| 12:46pm | Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy | FW |
| 11:25am | Genmab: Positive developments priced in; time to take profits |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GENMAB A/S | Bio Therapeutic Drugs | +28.25% | +44.78% | +86.01% | +96.67% | +28.94% | 34.47B |
-
|
-
|
-
|
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
